| abstract |
Engineered antibodies against human IL-17A and uses thereof are provided. In one embodiment, the invention provides an antibody molecule or binding fragment thereof that binds to and inhibits the activity of a binding compound, such as human IL-17A. In some embodiments, the binding molecule comprises at least one antibody light chain variable (V L ) domain and at least one antibody heavy chain variable (V H ) domain or a binding fragment of these domains, wherein V The L domain includes at least a specific number of complementarity determining regions (CDRs) having a sequence selected from SEQ ID NOs: 11-13, and the V H domain is at least a specific CDR having a sequence selected from SEQ ID NOs: 14-20 Including a number, where the specific number is 1, 2 or 3. |